Embolx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.63M

  • Investors
  • 14

Embolx General Information

Description

Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. The company's microcatheters set a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues, enabling doctors to improve treatment for various conditions and kill the tumor.

Contact Information

Website
www.embolx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 530 Lakeside Drive
  • Suite 200
  • Sunnyvale, CA 94085
  • United States
+1 (408)
Primary Industry
Surgical Devices
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 530 Lakeside Drive
  • Suite 200
  • Sunnyvale, CA 94085
  • United States
+1 (408)

Embolx Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Embolx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 31-Oct-2022 $1.63M Completed Generating Revenue
11. Later Stage VC 01-Jan-2022 Completed Generating Revenue
10. Later Stage VC (Series C) 01-Jul-2021 Completed Generating Revenue
9. Debt - PPP 13-Apr-2020 Completed Generating Revenue
8. Accelerator/Incubator 01-Jun-2019 Completed Generating Revenue
7. Grant 06-Apr-2018 Completed Generating Revenue
6. Early Stage VC (Series B) 01-Nov-2017 Completed Generating Revenue
5. Early Stage VC (Series A2) 15-Jun-2016 Completed Generating Revenue
4. Grant 25-Sep-2015 $1.11M $1.75M Completed Generating Revenue
3. Grant 01-Jan-2015 $447K $1.75M Completed Generating Revenue
To view Embolx’s complete valuation and funding history, request access »

Embolx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A2
Series A1 404,836 8% $3.74 $3.74 1x $3.74 14.41%
Series A 151,874 8% $3.29 $3.29 1x $3.29 5.4%
To view Embolx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Embolx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of balloon occlusion microcatheters designed to treat cancerous tumors, benign prostatic hyperplasia, and uter
Surgical Devices
Sunnyvale, CA
15 As of 2025

Westminster, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embolx Competitors (1)

One of Embolx’s competitors is TriSalus Life Sciences, a Formerly VC-backed company based in Westminster, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TriSalus Life Sciences Formerly VC-backed Westminster, CO
You’re viewing 1 of 1 competitors. Get the full list »

Embolx Patents

  • 71

    Total Documents Applications and Grants

  • Total Patents Families

  • 34

    Granted

  • 14

    Pending

  • Expiring in next 12 mo

Embolx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230226328-A1 Catheters adapted for agent delivery Pending 02-Jul-2021
EP-4363019-A1 Catheters adapted for agent delivery Pending 12-Jun-2021
US-20220296864-A1 Catheters and methods of manufacture and use Pending 27-May-2020
EP-4017568-A1 Catheters and methods of manufacture and use Inactive 20-Aug-2019
JP-2022545218-A Catheter, method of manufacture and method of use Pending 20-Aug-2019 A61M25/10
To view Embolx’s complete patent history, request access »

Embolx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embolx Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Acorn Campus Taiwan Venture Capital Minority
Keiretsu Forum Angel Group Minority
Xandex Ventures Corporate Venture Capital Minority
MedTech Innovator Accelerator/Incubator Minority
VI Ventures Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

Embolx FAQs

  • When was Embolx founded?

    Embolx was founded in 2013.

  • Where is Embolx headquartered?

    Embolx is headquartered in Sunnyvale, CA.

  • What is the size of Embolx?

    Embolx has 15 total employees.

  • What industry is Embolx in?

    Embolx’s primary industry is Surgical Devices.

  • Is Embolx a private or public company?

    Embolx is a Private company.

  • What is Embolx’s current revenue?

    The current revenue for Embolx is .

  • How much funding has Embolx raised over time?

    Embolx has raised $16.5M.

  • Who are Embolx’s investors?

    Acorn Campus Taiwan, Keiretsu Forum, Xandex Ventures, MedTech Innovator, and VI Ventures are 5 of 14 investors who have invested in Embolx.

  • Who are Embolx’s competitors?

    TriSalus Life Sciences is a competitor of Embolx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »